Pharmacophore based virtual screening, molecular docking and biological evaluation to identify novel PDE5 inhibitors with vasodilatory activity.

[1]  Koteswara Rao Valasani,et al.  Structure Based Design, Synthesis, Pharmacophore Modeling, Virtual Screening, and Molecular Docking Studies for Identification of Novel Cyclophilin D Inhibitors , 2014, J. Chem. Inf. Model..

[2]  Y. Mo,et al.  In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features , 2013, Drug design, development and therapy.

[3]  Youyong Li,et al.  Discovery of Rho-kinase inhibitors by docking-based virtual screening. , 2013, Molecular bioSystems.

[4]  Kunal Roy,et al.  Some case studies on application of “rm2” metrics for judging quality of quantitative structure–activity relationship predictions: Emphasis on scaling of response data , 2013, J. Comput. Chem..

[5]  K. Roy,et al.  Predictive Modeling of Antioxidant Coumarin Derivatives Using Multiple Approaches: Descriptor-Based QSAR, 3D-Pharmacophore Mapping, and HQSAR , 2012, Scientia pharmaceutica.

[6]  M. Arooj,et al.  3D QSAR Pharmacophore Modeling, in Silico Screening, and Density Functional Theory (DFT) Approaches for Identification of Human Chymase Inhibitors , 2011, International journal of molecular sciences.

[7]  S. Sakkiah,et al.  Combined ligand based pharmacophore modeling, virtual screening methods to identify critical chemical features of novel potential inhibitors for phosphodiesterase-5 , 2011 .

[8]  Kou-Juey Wu,et al.  Induction of HSPA4 and HSPA14 by NBS1 overexpression contributes to NBS1-induced in vitro metastatic and transformation activity , 2011, Journal of Biomedical Science.

[9]  F. Montes,et al.  Caffeine's Vascular Mechanisms of Action , 2010, International journal of vascular medicine.

[10]  S. Rybalkin,et al.  Multiple Affinity States of cGMP-Specific Phosphodiesterase for Sildenafil Inhibition Defined by cGMP-Dependent and cGMP-Independent Mechanisms , 2010, Molecular Pharmacology.

[11]  T. Singh,et al.  Clinical use of sildenafil in pulmonary artery hypertension , 2010, Expert review of respiratory medicine.

[12]  N. Suresh,et al.  Pharmacophore Modeling and Virtual Screening Studies to Design Potential Protein Tyrosine Phosphatase 1B Inhibitors as New Leads , 2010 .

[13]  D. Halpin.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD , 2008, International journal of chronic obstructive pulmonary disease.

[14]  Nicolas Foloppe,et al.  Conformational Sampling of Druglike Molecules with MOE and Catalyst: Implications for Pharmacophore Modeling and Virtual Screening , 2008, J. Chem. Inf. Model..

[15]  Jun Wang,et al.  Methyl (11aS)-1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo-[3',4':1,2]pyridin[3,4-b]indol-2-substituted acetates: synthesis and three-dimensional quantitative structure-activity relationship investigation as a class of novel vasodilators. , 2008, Journal of medicinal chemistry.

[16]  V. Kapur,et al.  The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems , 2007, International Journal of Impotence Research.

[17]  Kavitha Bharatham,et al.  Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors. , 2007, Journal of molecular graphics & modelling.

[18]  Thy-Hou Lin,et al.  Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. , 2006, Journal of medicinal chemistry.

[19]  C. S. Patil,et al.  Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. , 2004, Methods and findings in experimental and clinical pharmacology.

[20]  Tingjun Hou,et al.  Recent development and application of virtual screening in drug discovery: an overview. , 2004, Current pharmaceutical design.

[21]  S. Jin,et al.  Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling , 2002, Trends in Endocrinology & Metabolism.

[22]  M. Conti.  Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. , 2000, Molecular endocrinology.

[23]  J. Kotera,et al.  1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor. , 1999, Journal of medicinal chemistry.

[24]  B. Neustadt,et al.  Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity. , 1997, Journal of medicinal chemistry.